The Defense Health Agency awarded the University of Florida $996,470 under the Military Medical Research and Development program (CFDA 12.420) on November 1, 2026, to enhance immunotherapy treatment response in triple-negative breast cancer through development of a novel molecular glue degrader of the COREST complex.
Work is performed in Gainesville, Florida from November 1, 2026 through October 31, 2029. The University of Florida's Division of Sponsored Research serves as recipient, administering the project grant.